Study of ALXN2050 in Participants With Renal Impairment
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study will investigate the impact of impaired renal function on the plasma
pharmacokinetics of ALXN2050 in order to provide dosing recommendations for future
indications in individuals with impaired renal function.